Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intravenous Administration JMKX003142 in Chinese Healthy Subjects: A Randomized, Double-Blind, Placebo-Controlled, Single, and Multiple Ascending Dose Phase I Clinical Trial.

Drug Des Devel Ther · 2026 · PMC12970034 · PMID 41810128

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a slight trendno p-value reported

Within the dose range of 0.1 mg to 2 mg, the C max of JMKX003142 increased in a generally dose-proportional manner; while the AUC 0-inf exhibited a slight trend toward greater than dose proportionality.

also in 4,078 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.